NuLife Sciences, Inc. (OTCMKTS:NULF) Files An 8-K Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement

From December 14, 2016 to December 22, 2016, NuLife Sciences,
Inc. (the Company) entered into those certain Note Purchase
Agreements (collectively, the Purchase Agreements) in connection
with the issuance of certain convertible promissory notes
(collectively, the Purchase Notes) in the aggregate principal
amount of $145,000. All of the Purchase Notes are due upon
demand, provided however, that the holder thereof cant make
demand until after Ninety (90) days from the date of issuance
(the Maturity Date). The Purchase Notes bear interest at the rate
of 8% compounded monthly. The Purchase Notes, together with all
interest as accrued, are each convertible into shares of the
Companys common stock at .11 per share. The Purchase Agreements
and the Purchase Notes contain representations, warranties,
conditions, restrictions, and covenants of the Company that are
customary in such transactions with smaller companies. Copies of
the Purchase Agreements and Purchase Notes are included as an
Exhibit hereto.

Item 2.03 Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a
Registrant.

From December 14, 2016 to December 22, 2016, the Company executed
the Purchase Agreements and issued the Purchase Notes as
described in Item 1.01 above. The Purchase Notes may be
accelerated by the holders thereof in the event of default. In
addition, the amounts due and payable under the Purchase Notes
(and, consequently, the number of shares of common stock
convertible thereunto) may be increased to 150% of the principal
and interest amounts of the Purchase Notes. The Purchase Notes
are a direct financial obligation of the Company and are
considered a current liability of the Company for accounting
purposes.

Item 3.02 Unregistered Sales of Equity
Securities.

As described in Item 1.01 above, from December 14, 2016 to
December 22, 2016, the Company issued the Purchase Notes,
convertible into equity securities of the Company as described in
Item 1.01 above.

In respect of the aforementioned convertible note issuances of
the Company, the note holders are each an accredited investor as
such term is defined by rules promulgated by the Securities and
Exchange Commission (SEC). No solicitation was made and no
underwriting discounts were given or paid in connection with
these transactions. The Company believes that the issuance of the
convertible promissory notes to their respective agreements were
exempt from registration with the SEC to Section 4(2) of the
Securities Act of 1933.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

4.1 Convertible Promissory Note issued to Equity Trust Company as
custodian fbo Gideon Bernstein IRA;

4.2 Convertible Promissory Note issued to Brett Conrad TR FBO
Conrad Group;

4.3 Convertible Promissory Note issued to Nicholas Halsey;

4.4 Convertible Promissory Note issued to Postcard Capital Group;

4.5 Convertible Promissory Note issued to Ash Management, Inc.;

10.1 Note Purchase Agreement between NuLife Sciences, Inc. and
Equity Trust Company as custodian fbo Gideon Bernstein IRA
Account 200185952;

10.2 Note Purchase Agreement between NuLife Sciences, Inc. and
Brett Conrad TR FBO Conrad Group;

10.3 Note Purchase Agreement between NuLife Sciences, Inc. and
Nicholas Halsey;

10.4 Note Purchase Agreement between NuLife Sciences, Inc. and
Postcard Capital Group;

10.5 Note Purchase Agreement between NuLife Sciences, Inc. and
Ash Management, Inc.

About NuLife Sciences, Inc. (OTCMKTS:NULF)

NuLife Sciences, Inc., formerly SmooFi, Inc., is a biomedical company. The Company’s segments include Online marketplace and community, and Operations, Consulting and Advisory Services in the Cannabis Industry. The Company, through its subsidiary, NuLife BioMed, Inc., is focused on advancing human organ transplant technology and medical research. The Company is focused on a method (NuLife Technique) that could eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. Its technique is suitable for a range of clinical indications. The Company has completed discovery phase for its technique, and is entering a Preclinical phase involving animal experiments on its pathway to commercialization. The Company, through NuLife Technologies, Inc., is focused on providing an online marketplace and community to assist in creating jobs and enable entrepreneurs and service providers to offer health related products and services within local markets.

NuLife Sciences, Inc. (OTCMKTS:NULF) Recent Trading Information

NuLife Sciences, Inc. (OTCMKTS:NULF) closed its last trading session 00.000 at 0.700 with 15,000 shares trading hands.